SLC38A7 and hepatocellular carcinoma: Mo et al. [33] and Missiaen et al. [34] demonstrated that inhibiting the dysregulated NF-κB/RAP1 signaling pathway or targeting amino acid transporters could offer a viable approach for targeted therapy for HCC in clinical settings.